Search

Displaying results 4991 - 5000 of 10000 in total
  1. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  2. Drug

    TSHA-118

    go.drugbank.com/drugs/DB16996
    Experimental

    TSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.

  3. Drug

    Esuberaprost

    go.drugbank.com/drugs/DB18464
    Investigational

    Esuberaprost (GP-1681), a drug intended for participants with pulmonary arterial hypertension, was under investigation in clinical trial NCT03657095 to evaluate its efficacy and safety.

  4. Drug

    Vibecotamab

    go.drugbank.com/drugs/DB18872
    Investigational

    Vibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure).

  5. Drug

    Anti-CD19 CAR-T cells

    go.drugbank.com/drugs/DB21913
    Investigational

    CD19 CAR-T is under investigation in clinical trial NCT05618041 (The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies).

  6. Drug

    Zamubafusp alfa

    go.drugbank.com/drugs/DB32269
    Investigational

    [L55038] It consists of a humanized IgG1 and p5R which is a pan-amyloid reactive peptide.[L55038]

  7. Drug

    UDP-alpha-D-xylose

    go.drugbank.com/drugs/DB01713
    Experimental

    The decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans.

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]

  9. Drug

    Troxipide

    go.drugbank.com/drugs/DB13419
    Experimental

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  10. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

    Categories: Corticosteroids for Systemic Use